Misa Kusumoto

Ms. Misa Kusumoto

University of Tsukuba, Faculty of Medicine
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Bryan MathisBryan Mathis
Bryan Mathis
MKMisa Kusumoto
Misa Kusumoto
Alexander ZaboronokAlexander Zaboronok
Alexander Zaboronok
YHYuji Hiramatsu
Yuji Hiramatsu
Asthma is a life-altering, chronic disease of heterogenous origin that features a complex interplay of immune and environmental signaling. Although very little progress has been made in prevention, diverse types of medications and delivery systems, including nanoscale systems, have been or are currently being developed to control airway inflammation and prevent exacerbations and fibrosis. These medications are delivered through mechanical methods, with various inhalers (with benefits and drawbacks) existing, and new types offering some variety in delivery. Of particular interest is the progress being made in nanosized materials for efficient penetration into the epithelial mucus layer and delivery into the deepest parts of the lungs. Liposomes, nanoparticles, and extracellular vesicles, both natural and synthetic, have been explored in animal models of asthma and have produced promising results. This review will summarize and synthesize the latest developments in both macro-(inhaler) and micro-sized delivery systems for the purpose of treating asthma patients.

5 November 2023 in Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
Soichiro SaekiSoichiro Saeki
Soichiro Saeki
MKMisa Kusumoto
Misa Kusumoto
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.

6 April 2021 in Allergies
Verified
Journal Article
Open access
PDF file
MKMisa Kusumoto
Misa Kusumoto
Bryan MathisBryan Mathis
Bryan Mathis
The global COVID-19 pandemic has brought respiratory disease to the forefront of public health, but asthma prevalence has been rising globally for decades. Asthma is mediated by errant immune activation and airway remodeling, but the influences of environment, nutrition, and comorbidities (e.g., asthma-chronic obstructive pulmonary disorder-overlap [ACO]) are still poorly understood. Even as a new generation of biologic-based treatments offer better airway control and reductions in mortality, a lack of prophylactic treatments and mechanistic understanding complicates efforts to prevent pathogenesis. This review will explicate and synthesize current knowledge on the effect of ACO and biologics (omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab) on pathogenesis, treatment, and prognosis.

1 September 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MKMisa Kusumoto
Misa Kusumoto
Akihiko ShimomuraAkihiko Shimomura
Akihiko Shimomura
CSChikako Shimizu
Chikako Shimizu